• Roche flagged new Alzheimer’s disease data at AAIC 2026, centered on investigational trontinemab with long-term safety, amyloid clearance, and biomarker updates.
• Phase III dosing for TRONTIER 1 and 2 in early symptomatic Alzheimer’s was informed by modeling from the Phase Ib/IIa open-label extension study.
• Roche disclosed the design of PrevenTRON, a Phase III trontinemab trial in preclinical Alzheimer’s targeting cognitively unimpaired, high-risk individuals.
• Elecsys pTau217 blood test received CE mark as a rule-in, rule-out aid for amyloid pathology; additional performance data in primary, secondary care due at AAIC.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20260706139373) on July 07, 2026, and is solely responsible for the information contained therein.